Omnicell, Inc. (NASDAQ:OMCL) Stock Position Reduced by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd cut its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 58.1% during the third quarter, HoldingsChannel.com reports. The firm owned 11,092 shares of the company’s stock after selling 15,351 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Omnicell were worth $484,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in Omnicell by 1.4% during the first quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock valued at $165,200,000 after purchasing an additional 80,312 shares in the last quarter. Pacer Advisors Inc. grew its position in Omnicell by 32.6% in the second quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock worth $56,047,000 after acquiring an additional 508,789 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Omnicell by 0.3% in the second quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company’s stock worth $31,955,000 after acquiring an additional 3,570 shares in the last quarter. Victory Capital Management Inc. grew its position in Omnicell by 11,982.3% in the third quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock worth $50,071,000 after acquiring an additional 1,138,921 shares in the last quarter. Finally, Federated Hermes Inc. grew its position in Omnicell by 1,113.6% in the second quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock worth $26,830,000 after acquiring an additional 909,480 shares in the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Barclays boosted their target price on shares of Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Craig Hallum boosted their target price on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Bank of America reissued a “neutral” rating and issued a $57.00 target price (up from $44.00) on shares of Omnicell in a research report on Thursday, October 31st. StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, Wells Fargo & Company upped their price objective on shares of Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a report on Monday, October 14th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, Omnicell presently has a consensus rating of “Hold” and a consensus price target of $52.00.

Omnicell Trading Down 3.9 %

NASDAQ OMCL opened at $46.59 on Friday. The company has a fifty day simple moving average of $44.55 and a 200 day simple moving average of $37.94. The company has a market cap of $2.16 billion, a P/E ratio of -119.46, a P/E/G ratio of 36.82 and a beta of 0.81. Omnicell, Inc. has a 1 year low of $25.12 and a 1 year high of $55.74.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.